Glow LifeTech Announces the Start of a Clinical Trial of Artemic Support Using MyCell Technology in Patients With Long-Term COVID. known

News and research before you hear about it on CNBC and others. Request your one-week free trial of StreetInsider Premium here.

Toronto, Ontario – (Newsfile Corp. – December 24, 2021) – Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FWB: 9DO) (“Glow” or the “Company”), a biotechnology innovator who is scientifically backed next-generation natural ingredients, is pleased to announce that they are launching a clinical study (the “Study”) to investigate the effects of their proprietary natural health product Artemic Support® with MyCell® technology on patients with Long COVID Syndrome.

Post-Acute COVID Syndrome (PACS) or “Long COVID” presents as a variety of persistent symptoms that patients may experience four or more weeks after first becoming infected with SARS-COV-2[1]. It is estimated that around 10 to 35% of all COVID patients are affected by Long Covid[2], and it is generally believed that the inflammatory response is fundamental to symptom persistence. Therefore, the ability to reduce inflammation could improve patient outcomes, and this study aims to validate such a framework for Artemic Support®.

Artemic Support® is a natural health product made from curcumin, boswellia and vitamin C, which was developed to reduce inflammatory reactions and was formulated with ingredients from MyCell® Technology to increase bioavailability and enable faster, more effective cellular absorption of natural active ingredients. This new innovation is the second product in the company’s Artemic line of products to enter the clinical trial phase to determine safety and efficacy against SARS2-COV-2-related diseases. In April 2020, the company announced that, following the successful results of a Phase II clinical trial in patients diagnosed with moderate COVID-19, it has submitted its first product, Artemic “Rescue, to Health Canada as a natural health product.[3]

Study details

The study is being carried out in collaboration with Swiss PharmaCan, the sponsor of the study, and Glow as a co-sponsor alongside MGC Pharmaceuticals. The low-intervention study is one-armed, open-ended and includes 150 patients with Post Acute COVID Syndrome (PACS) and is carried out by UniversalDoctors in 3 primary care centers in Catalonia, Spain. Patients will take Artemic Support® under their doctor’s supervision for 6 weeks, and their progress will be measured throughout the period to see if symptoms are being reduced while looking for adverse events.

The approval of the ethics committee was obtained and the study with 50 patients included is already ongoing. The study is expected to be completed in February 2022, provided that the target numbers are reached. The results will be published in the second quarter of 2022. This is considered a pilot study that will be used to obtain initial data on the safety and effectiveness of Artemic Support®; Depending on the results of the current study, a more comprehensive randomized study will follow.

“I am pleased with the First Patient In on December 13th as I expect very valuable results on the safety and effectiveness of Artemic Support®, based on its groundbreaking MyCell technology and the potential benefits for millions of people suffering from Long COVID, who previously had no therapeutic options, “said study organizer Dr. Dieter L. Russmann MD, Senator hc, from Swiss PharmaCan.

“Scientific validation and research are of paramount importance to the ongoing commercial endeavors of the MyCell® technology. Glow is pleased to be involved in important work in support of long-term COVID symptoms and the potential health benefits of its cutting-edge ingredients with our partners confirm, “said Clark Kent, CEO of Glow LifeTech.

MyCell® Technology is Glow’s proprietary, naturally-derived delivery system that dramatically improves the absorption, bioavailability, and potency of natural ingredients like cannabinoids, vitamins, botanicals, and more. It converts natural substances that are difficult to absorb into water-compatible concentrates with a rapid onset of action, high absorption and precise dosing. The versatility of the MyCell® enhanced concentrates allows them to run a wide variety of product formats including: droppers, beverages, groceries, topicals, and capsules.

Latest news

The company recently announced that it has completed the expansion of its licensed processing facility in Canada and has commenced commissioning of its reactor production facilities. The full story here:

SUBSCRIBE: For more information about Glow or to subscribe to the company’s email list, please visit:

About Glow LifeTech Corp.
Glow LifeTech is a Canada-based biotechnology company focused on creating nutraceutical and cannabinoid-based products with dramatically improved bioavailability, absorption, and potency. Glow owns the rights to the groundbreaking, plant-based MyCell Technology® delivery system, which converts poorly absorbed natural substances into improved water-compatible concentrates that release the full healing potential of the valuable substances.


James Van Staveren
Annealing LifeTech Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 diam. 2
[email protected]

Bernhard Langer
EU investor relations
+49 (0) 177 774 2314
[email protected]

About Swiss Pharmacan

Micelle Technology AG, parent company of Swiss PharmaCan, is a dynamic organization dedicated to research and development with natural active ingredients (i.e. vitamins and minerals) to improve human health. As one of the leading innovators of plant-based micelle concentrates, Micelle Technology AG offers a unique technology that enables the company to exploit the full potential of plant-based active ingredients.


About UniversalDoctor

UniversalDoctor: The Digital Global Health Company is a social company that works together to develop technology solutions to improve health outcomes around the world. UniversalDoctor has worked with international organizations and partners in over two dozen countries to develop nearly 30 technology solutions, ranging from clinical decision support tools, mobile data acquisition systems, clinical trial data acquisition tools, clinical and remote monitoring platforms to intelligent chatbots. The latest introduction of tools is called UhDa Tools: UniversalHealth Digital Access Tools.


About MGC Pharmaceuticals Ltd.

MGC Pharma is a biopharmaceutical company with a “Nature to Medicine” strategy at the forefront of emerging markets for phytocannabinoids and herbal medicines. The company’s mission is to build an innovative, global biopharmaceutical company that provides standardized, affordable herbal medicines with the highest regulatory compliance for selected global markets.


Cautionary Statement Regarding Forward-Looking Information

Except for historical facts, this press release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is often identified by words such as “plan,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” and other similar words or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on opinions and estimates at the time the statements were made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements, including, but not limited to delays or uncertainties in regulatory approvals, including those of the CSE. Forward-looking information involves uncertainties, including factors that are beyond the control of the company. There are no representations that the commercialization plans for the technology described in this press release will be effective on the terms or time frames described herein. The company assumes no obligation to update forward-looking information if circumstances or management’s estimates or opinions change, except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information to help identify risks and uncertainties that could affect financial results is included in the Company’s filings with Canadian Securities and Markets available at



[3] See Glow press release dated April 27, 2021

To view the source version of this press release, please visit

Comments are closed.